CENATAC divergent transcript

The term "CENATAC divergent transcript" or "CENATAC-DT" appears to be a non-standard or potentially incorrect designation. Evidence suggests that the canonical target is CENATAC, a protein-coding gene, but "CENATAC divergent transcript" most likely refers to a noncoding RNA produced by divergent transcription from the CENATAC locus, rather than a recognized therapeutic target or well-characterized molecular entity. The designation is problematic. The phrase "divergent transcript" generally refers to noncoding RNAs produced from promoters in the opposite direction to coding RNAs, a widespread regulatory phenomenon, not an individual, well-characterized molecule. "CENATAC-DT" is not a commonly used or accepted identifier for a specific molecule or target. "CENATAC divergent transcript" refers generically to a noncoding RNA species that may be transcribed in the opposite direction to the CENATAC gene at its promoter—a phenomenon known as divergent transcription. While divergent transcripts are common in the genome and can play regulatory roles, there is no evidence for a specifically functional or clinically meaningful "CENATAC divergent transcript." The protein-coding gene CENATAC itself encodes a component of the minor spliceosome involved in splicing A-type minor introns and is essential for chromosomal stability. No divergent transcript for CENATAC is currently classified as a distinct therapeutic target or biomolecule in major genomic or proteomic databases. In summary, "CENATAC divergent transcript" is not a standardized entity or therapeutic target and lacks sufficient information in the scientific literature to be described in a structured, canonical manner.

Other names

divergently transcribed noncoding RNA at CENATAC locus